High-integrity nanoemulsions formulation of resiquimod (R848) enhances stability and delivery for triple negative breast cancer immunotherapy
Ahmed Salem, Sara Attia, Samah El‐Ghlban, Ahmed Saad Montaser, Mohamed Fayed Abdelhameed, Maged W. Helmy, Mohamed F. Attia
This paper develops a nanoemulsions formulation of resiquimod to improve its stability and delivery for TNBC immunotherapy, showing enhanced autophagy and immune checkpoint modulation.
bioRxiv · Apr 4, 2025 · PreprintImmunology